Atara Biotherapeutics (ATRA) interim CFO Kevin Sarney files initial Form 3
Rhea-AI Filing Summary
Atara Biotherapeutics, Inc. reported that Kevin G. Sarney, serving as Interim CFO, filed an initial Form 3 statement of beneficial ownership. The filing lists him as an officer but shows no reported transactions or holdings details in the provided data.
Positive
- None.
Negative
- None.
Key Terms
Form 3, Interim CFO, beneficial ownership
3 terms
Form 3 regulatory
"filed an initial Form 3 statement of beneficial ownership"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Interim CFO financial
"Kevin G. Sarney, serving as Interim CFO"
An interim CFO is a temporary chief financial officer hired to run a company’s finance operations during a leadership transition, a search for a permanent hire, or while specific financial issues are resolved. Investors pay attention because this person manages budgeting, financial reporting and communications with shareholders—like a substitute driver keeping a car on course—so their competence affects short‑term financial stability, the accuracy of public reports, and market confidence.
beneficial ownership financial
"filed an initial Form 3 statement of beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Atara Biotherapeutics (ATRA) Form 3 filing for Kevin G. Sarney show?
The Form 3 records Kevin G. Sarney as an officer of Atara Biotherapeutics. He is listed as Interim CFO, and the provided data shows no reported transactions or derivative positions associated with this initial beneficial ownership statement.
Who is the reporting person in Atara Biotherapeutics (ATRA) latest Form 3?
The reporting person is Kevin G. Sarney, identified as an officer of Atara Biotherapeutics. His officer title is Interim CFO, and he is not listed as a director or ten percent owner in the provided filing information.
Does the Atara Biotherapeutics (ATRA) Form 3 for Kevin G. Sarney report any stock transactions?
No stock transactions are reported in this Form 3. The transaction summary shows zero buys, zero sells, and no derivative exercises or other transactions, indicating only an initial ownership report without trading activity in the provided data.
Is Kevin G. Sarney a ten percent owner of Atara Biotherapeutics (ATRA) according to the Form 3?
According to the filing data, Kevin G. Sarney is not a ten percent owner. He is flagged as an officer with the title Interim CFO, while the ten percent owner indicator is marked as zero in the disclosure.
What does the transactionSummary section in the ATRA Form 3 indicate?
The transactionSummary section indicates no activity for Kevin G. Sarney. BuyCount, sellCount, acquireCount, disposeCount, and exerciseCount are all zero, and netBuySellDirection is labeled neutral, reflecting the absence of reported trades or derivative actions.